Inclusion on the list of medicines reimbursed by National Health Insurance and approved for hospital use.
-
Clinical Benefit
Substantial
The actual benefit of this medicinal product is substantial.
Clinical Added Value
minor
PREZISTA (darunavir), co-administered with a low dose of ritonavir, provides a minor improvement in actual benefit (level IV) in terms of virological efficacy compared to KALETRA in a population comprising only treatment-naïve patients at an advanced stage of the infection (VL ≥ 100 000 copies/ml).
Listen
